Travers Smith LLP has advised long-standing client Inflexion on the refinancing of CNX Therapeutics (CNX) with a new debt facility from credit funds managed by global alternative investment manager Ares Management (Ares).
CNX is a speciality pharmaceutical company with a focus on improving access to essential medicines. The funding provided by Ares will enable new strategic partnerships and transactions across the pharmaceutical sector, accelerating CNX's growth strategy across Europe.
The Travers Smith team was led by Head of Leveraged Finance Matthew Ayre, Senior Associate Jason Larkins, and Associate Shehan Canagasingham.
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.